Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $187.5 million.

  • Madrigal Pharmaceuticals' Change in Accured Expenses rose 111840.57% to $187.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 34223.96%. This contributed to the annual value of $34.7 million for FY2024, which is 244402.43% up from last year.
  • Madrigal Pharmaceuticals' Change in Accured Expenses amounted to $187.5 million in Q3 2025, which was up 111840.57% from $33.3 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Change in Accured Expenses registered a high of $187.5 million during Q3 2025, and its lowest value of -$6.3 million during Q4 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' median Change in Accured Expenses value was $3.3 million (recorded in 2021), while the average stood at $15.8 million.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Change in Accured Expenses plummeted by 28148.73% in 2021 and then skyrocketed by 171295.64% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Change in Accured Expenses stood at -$3.5 million in 2021, then surged by 443.56% to $11.9 million in 2022, then tumbled by 37.87% to $7.4 million in 2023, then plummeted by 185.59% to -$6.3 million in 2024, then surged by 3073.0% to $187.5 million in 2025.
  • Its Change in Accured Expenses stands at $187.5 million for Q3 2025, versus $33.3 million for Q2 2025 and -$530000.0 for Q1 2025.